Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as mRNA-1365 (Profile 2)
mRNA-1365 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| mRNA-1365 (Profile 2) Dose Level 1 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 1 on Day 1. |
| mRNA-1365 (Profile 2) Dose Level 2 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 2 on Day 1. |
| mRNA-1365 (Profile 2) Dose Level 3 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 3 on Day 1. |
| mRNA-1345 (Profile 1) | ACTIVE_COMPARATOR | Participants will receive 1 injection of mRNA-1345 (Profile 1) on Day 1. |
| mRNA-1345 (Profile 3) | ACTIVE_COMPARATOR | Participants will receive 1 injection of mRNA-1345 (Profile 3) on Day 1. |
| Name | Type | Description |
|---|---|---|
| mRNA-1365 (Profile 2) | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1345 (Profile 1) | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1345 (Profile 3) | BIOLOGICAL | Sterile liquid for injection |
Key Inclusion Criteria: * In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history and physical examination. * Body mass index within the range 18.5 to 35 kg/m2 (inclusive). Key Exclusion Criteria: * History of anaphylaxis or ...
mRNA-1365 is an investigational vaccine developed by Moderna, Inc. for respiratory syncytial virus (RSV). It is also being studied against human metapneumovirus (hMPV). The vaccine is in Phase 1 clinical development and has not been approved by any regulatory agency.
mRNA-1365 is being developed to prevent respiratory syncytial virus (RSV) in older adults. The Phase 1 study enrolls healthy adults aged 60 years and older. It is also being evaluated against human metapneumovirus (hMPV), and it remains investigational.
mRNA-1365 targets the RSV prefusion F glycoprotein and the hMPV F protein. Both are surface glycoproteins that the vaccine is designed to elicit immune responses against. Targeting the prefusion F conformation is intended to generate neutralizing antibodies against these respiratory viruses.
mRNA-1365 is being developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the Phase 1 clinical trial evaluating the vaccine in older healthy adults.
mRNA-1365 is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA or any other regulatory authority. The single Phase 1 trial is currently recruiting participants.
mRNA-1365 is being studied in one active Phase 1 trial, NCT07764237, titled a study to investigate safety, reactogenicity, and immunogenicity of mRNA-1365 (Profile 2) in older healthy adults. The trial is recruiting 375 participants across Canada and the United Kingdom.
Yes, mRNA-1365 (Profile 2) refers to the same investigational vaccine as mRNA-1365. The Profile 2 designation appears in the Phase 1 trial title, NCT07764237, which evaluates the vaccine in healthy adults aged 60 years and older.